The CHMP recommended marketing authorization for Fluad and Flucelvax vaccines for influenza immunization in Europe, ideal for children from 2 years old, adults, and those with comorbidities. They recommended a revised composition for Nuvaxovid targeting the JN.1 variant of the SARS-CoV-2 virus and updating Bimervax targeting the Omicron XBB.1.16 SARS-CoV-2 subvariant for the 2024/2025 vaccination campaign. Fluad and Flucelvax are both effective at reducing influenza risk and have manageable side effects. The updated vaccines for COVID-19 have shown cross-reactivity and safety in clinical trials. These recommendations are pending approval from the European Commission.
Source link
Health Information Management